Cargando…
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
Most subjects develop antibodies to SARS‐CoV‐2 following infection. In order to estimate the duration of immunity induced by SARS‐CoV‐2 it is important to understand for how long antibodies persist after infection in humans. Here, we assessed the persistence of serum antibodies following WT SARS‐CoV...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646652/ https://www.ncbi.nlm.nih.gov/pubmed/34580856 http://dx.doi.org/10.1002/eji.202149535 |
_version_ | 1784610503635501056 |
---|---|
author | Haveri, Anu Ekström, Nina Solastie, Anna Virta, Camilla Österlund, Pamela Isosaari, Elina Nohynek, Hanna Palmu, Arto A Melin, Merit |
author_facet | Haveri, Anu Ekström, Nina Solastie, Anna Virta, Camilla Österlund, Pamela Isosaari, Elina Nohynek, Hanna Palmu, Arto A Melin, Merit |
author_sort | Haveri, Anu |
collection | PubMed |
description | Most subjects develop antibodies to SARS‐CoV‐2 following infection. In order to estimate the duration of immunity induced by SARS‐CoV‐2 it is important to understand for how long antibodies persist after infection in humans. Here, we assessed the persistence of serum antibodies following WT SARS‐CoV‐2 infection at 8 and 13 months after diagnosis in 367 individuals. The SARS‐CoV‐2 spike IgG (S‐IgG) and nucleoprotein IgG (N‐IgG) concentrations and the proportion of subjects with neutralizing antibodies (NAb) were assessed. Moreover, the NAb titers among a smaller subset of participants (n = 78) against a WT virus (B) and variants of concern (VOCs): Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) were determined. We found that NAb against the WT virus persisted in 89% and S‐IgG in 97% of subjects for at least 13 months after infection. Only 36% had N‐IgG by 13 months. The mean S‐IgG concentrations declined from 8 to 13 months by less than one third; N‐IgG concentrations declined by two‐thirds. Subjects with severe infection had markedly higher IgG and NAb levels and are expected to remain seropositive for longer. Significantly lower NAb titers against the variants compared to the WT virus, especially after a mild disease, suggests reduced protection against VOCs. |
format | Online Article Text |
id | pubmed-8646652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86466522021-12-06 Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans Haveri, Anu Ekström, Nina Solastie, Anna Virta, Camilla Österlund, Pamela Isosaari, Elina Nohynek, Hanna Palmu, Arto A Melin, Merit Eur J Immunol Immunity to infection Most subjects develop antibodies to SARS‐CoV‐2 following infection. In order to estimate the duration of immunity induced by SARS‐CoV‐2 it is important to understand for how long antibodies persist after infection in humans. Here, we assessed the persistence of serum antibodies following WT SARS‐CoV‐2 infection at 8 and 13 months after diagnosis in 367 individuals. The SARS‐CoV‐2 spike IgG (S‐IgG) and nucleoprotein IgG (N‐IgG) concentrations and the proportion of subjects with neutralizing antibodies (NAb) were assessed. Moreover, the NAb titers among a smaller subset of participants (n = 78) against a WT virus (B) and variants of concern (VOCs): Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) were determined. We found that NAb against the WT virus persisted in 89% and S‐IgG in 97% of subjects for at least 13 months after infection. Only 36% had N‐IgG by 13 months. The mean S‐IgG concentrations declined from 8 to 13 months by less than one third; N‐IgG concentrations declined by two‐thirds. Subjects with severe infection had markedly higher IgG and NAb levels and are expected to remain seropositive for longer. Significantly lower NAb titers against the variants compared to the WT virus, especially after a mild disease, suggests reduced protection against VOCs. John Wiley and Sons Inc. 2021-10-08 2021-12 /pmc/articles/PMC8646652/ /pubmed/34580856 http://dx.doi.org/10.1002/eji.202149535 Text en © 2021 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Immunity to infection Haveri, Anu Ekström, Nina Solastie, Anna Virta, Camilla Österlund, Pamela Isosaari, Elina Nohynek, Hanna Palmu, Arto A Melin, Merit Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans |
title | Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans |
title_full | Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans |
title_fullStr | Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans |
title_full_unstemmed | Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans |
title_short | Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans |
title_sort | persistence of neutralizing antibodies a year after sars‐cov‐2 infection in humans |
topic | Immunity to infection |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646652/ https://www.ncbi.nlm.nih.gov/pubmed/34580856 http://dx.doi.org/10.1002/eji.202149535 |
work_keys_str_mv | AT haverianu persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans AT ekstromnina persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans AT solastieanna persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans AT virtacamilla persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans AT osterlundpamela persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans AT isosaarielina persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans AT nohynekhanna persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans AT palmuartoa persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans AT melinmerit persistenceofneutralizingantibodiesayearaftersarscov2infectioninhumans |